Drug Combination Details
| General Information of the Combination (ID: C69281) | |||||
|---|---|---|---|---|---|
| Name | Flavopiridol NP Info | + | Venetoclax Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute myeloid leukemia
[ICD-11: 2A60]
|
Phase 2 | [1] | ||
|
Multiple myeloma
[ICD-11: 2A83]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BCL2L11 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H929 | CVCL_1600 | Plasma cell myeloma | Homo sapiens | ||
| U266B1 | CVCL_0566 | Plasma cell myeloma | Homo sapiens | |||
| OPM-2 | CVCL_1625 | Plasma cell myeloma | Homo sapiens | |||
| KMS-11 | CVCL_2989 | Plasma cell myeloma | Homo sapiens | |||
| RPMI-8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | |||
| KMS-28PE | CVCL_2995 | Plasma cell myeloma | Homo sapiens | |||
| In-vivo Model | The two models employed included an orthotopic murine model (NOD/SCID-gamma mice injected intravenously via tail vein with 5*106 PS-R (bortezomib-resistant U266) stably transfected with a construct encoding luciferase) and an immunocompetent model (C57BL/KaLwR1 mice injected intravenously via tail vein with 5*106 murine MM 5TGM1 cells stably expressing luciferase. | |||||
| Experimental
Result(s) |
Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. | |||||
